PFBT
KROS icon

Parkside Financial Bank & Trust’s Keros Therapeutics KROS Stock Holding History

Parkside Financial Bank & Trust’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$608 Hold
55
– – ﹤0.01% 2514
2025
Q4 		$1.12K Hold
55
– – ﹤0.01% 2308
2025
Q3 		$871 Hold
55
– – ﹤0.01% 2341
2025
Q2 		$735 Hold
55
– – ﹤0.01% 2364
2025
Q1 		$558 Buy
+55
New +$639 ﹤0.01% 2317

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Parkside Financial Bank & Trust's KROS Position: Q1 2026 in Review

Parkside Financial Bank & Trust held its Keros Therapeutics (KROS) position steady in Q1 2026 at 55 shares worth $608. The position accounts for ﹤0.01% of the portfolio, ranked #2514.

Parkside Financial Bank & Trust first reported a position in KROS in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.12K in Q4 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Parkside Financial Bank & Trust held 55 shares of Keros Therapeutics worth $608 as of Q1 2026.
  • Parkside Financial Bank & Trust left its Keros Therapeutics share count unchanged in Q1 2026.
  • Keros Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #2514 holding.
  • Parkside Financial Bank & Trust first reported a position in Keros Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Parkside Financial Bank & Trust's Keros Therapeutics position peaked at $1.12K in Q4 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.